A study of occupational exposure to antineoplastic drugs and fetal loss in nurses.

Details

• Personal Author:
  Hemminki K ; Hornung, Richard W. ; Lindbohm L ; Selevan SG
• Description:
  A case/control study was conducted to determine a possible relationship between fetal loss and exposure to antineoplastic drugs among nurses employed in 17 Finnish hospitals between 1973 and 1980. The study was limited to 124 nurses for whom fetal losses occurred and detailed pregnancy data was available and their 321 matched comparisons. Exposures over the entire pregnancy period were not linked to fetal loss. However, a study of exposure to antineoplastic drugs during the first trimester was positively linked with fetal loss; women with first trimester exposure were more than twice as likely to experience fetal loss. Specific drugs were also identified as being positively associated with fetal loss, including cyclophosphamide (50180), doxorubicin (23214928), and vincristine (57227), but it was not possible to separate them as exposure to more than one of these drugs was high. Mean gestation was slightly shorter for fetal losses among exposed women as compared with fetal losses among unexposed women. The authors recommend that specific precautionary measures be developed for the handling of these toxic but extremely useful medical agents. [Description provided by NIOSH]
• Subjects:
  Antineoplastic Agents Fetus Health Personnel Neoplasms Occupational Health Safety Urogenital Diseases Urogenital System
• Keywords:
  Antineoplastic-agents Chemotherapy Health-care-personnel NIOSH-Author Reproductive-system-disorders Short-term-exposure Transplacental-exposure
• ISSN:
  0028-4793
• Document Type:
  Text
• Genre:
  Journal Article
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  313
• Issue:
  19
• NIOSHTIC Number:
  nn:00175517
• Citation:
  N Engl J Med 1985 Nov; 313(19):1173-1178
• CAS Registry Number:
  (+)-Vincristine (CAS RN 57-22-7) ; Cyclophosphamide (CAS RN 50-18-0) ; Doxorubicin (CAS RN 23214-92-8)
• Federal Fiscal Year:
  1986
• NORA Priority Area:
  Disease and Injury: Fertility and Pregnancy Abnormalities
• Peer Reviewed:
  True
• Source Full Name:
  New England Journal of Medicine
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:54fcc492c1c317869e6a278849dfaf0ca551802d18cade8ac96b9f6476e63889d21845c8b1153c9b89a6cd52a9858e2ff891b7c69dcff60bd1641235cd6a9ec6
• Download URL:
  https://stacks.cdc.gov/view/cdc/185378/cdc_185378_DS1.pdf
• File Type:
  [PDF - 1012.94 KB ]